Rilpivirine Proves to be a Worthy HIV Opponent

Rilpivirine Proves to be a Worthy HIV Opponent

Rilpivirine 500287-72-9Rilpivirine is a non-nucleoside reverse transcriptase inhibitor {NTRI} known as the brand name Edurant. Rilpivirine is used to treat HIV-1 infection, and it is often dispensed alongside other antiretroviral agents. As a 25 milligram tablet designed to be taken once daily with food, rilpivirine is effective at decreasing the amount of HIV infection in the blood. Rilpivirine may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses like cancer or serious infections. Approved in May of 2011, rilpivirine as a first-line treatment, this novel medication has also been combined in a once-daily tablet called Eviplera. The combination drug, which received marketing approval in the EU in November 2011, is marketed as Complera in the United States. In addition, researchers are currently working on an injectable form of rilpivirine as a combination drug which utilizes nanoparticles. This injectable work in progress would be unique in that it would only need to be taken once a month.

The approval of rilpivirine was based on two Phase III studies which encompassed 48-weeks’ time. The results of these two Phase III studies showed that previously untreated individuals who received rilpivirine plus 2 nucleoside/nucleotide analogues had rates of viral suppression. The CD4 T-cell increases were similar to those of individuals who received efavirenz plus NRTIs as well. These encouraging results have been followed with other uplifting information. At the 18th Conference on Retroviruses and Opportunistic Infections, study results were presented which showed that patients who received rilpivirine were less likely to have low levels of vitamin D when compared to patients who received efavirenz. This is pertinent and reassuring to patients with HIV, as osteolmalacia, which is a type of bone loss and related to low vitamin D levels is known to commonly affect this patient population. Patients with HIV have lower vitamin D levels on average and are at a higher risk for bone loss. The approval and use of this efficacious medication offers hope to patients with HIV around the world.

LGM Pharma supplies the Rilpivirine CAS# 500287-72-9 API for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.


  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service